Enliven Therapeutics ELVN Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $85.86M+6.3% | $80.78M+25.1% | $64.57M+108% | $31.02M-19.3% | ||
| $33.8M+42.2% | $23.78M+25.4% | $18.96M+144% | $7.77M-40.2% | ||
| $119.66M+14.4% | $104.55M+25.2% | $83.53M+115% | $38.79M-24.6% | ||
| $119.66M+14.4% | $104.55M+25.2% | $83.53M+115% | $38.79M-24.6% | ||
| -$119.66M-14.4% | -$104.55M-25.2% | -$83.53M-115% | -$38.79M+24.6% | ||
| $16.01M+7.5% | $14.89M+24.4% | $11.97M+960% | $1.13M+385% | ||
| $15.96M+2.8% | $15.53M+30.0% | $11.95M+958% | $1.13M+1,847% | ||
| -$103.69M-16.5% | -$89.02M-24.4% | -$71.58M-90.1% | -$37.66M+26.7% | ||
| -$1.86+1.6% | -$1.89+13.3% | -$2.18+81.9% | -$12.04-288% | ||
| -$1.86+1.6% | -$1.89+13.3% | -$2.18+81.9% | -$12.04-408% | ||
| 220.9M+19.1% | 185.5M+17.0% | 158.5M+1,185% | 12.3M-83.5% | ||
| 220.9M+19.1% | 185.5M+17.0% | 158.5M+1,185% | 12.3M— | ||
| $16.01M+7.5% | $14.89M+24.4% | $11.97M+960% | $1.13M+385% | ||
| -$103.42M-16.1% | -$89.11M-24.7% | -$71.44M-63.6% | -$43.67M+15.1% | ||
| $279K+424% | -$86K-161% | $141K+503% | -$35K-75.0% | ||
| -$49K-2,350% | -$2K+90.9% | -$22K+76.6% | -$94K+46.3% | ||
| -$119.66M-14.4% | -$104.55M-25.2% | -$83.53M-115% | -$38.79M+24.6% | ||
| -$119.4M-14.5% | -$104.24M-25.2% | -$83.23M-116% | -$38.58M+24.9% | ||
| -$119.4M-14.5% | -$104.24M-25.2% | -$83.23M-116% | -$38.58M+24.9% | ||
| -$119.66M-14.4% | -$104.55M-25.2% | -$83.53M-115% | -$38.79M+24.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Enliven Therapeutics profitable?
- Enliven Therapeutics is not currently profitable: it reported a net loss of $98.8M over the trailing twelve months.
- What is Enliven Therapeutics's earnings per share?
- Enliven Therapeutics's diluted EPS over the trailing twelve months is $-1.67.
- Where does Enliven Therapeutics's income statement data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.